| First Author | Fauconnier M | Year | 2012 |
| Journal | J Immunol | Volume | 188 |
| Issue | 4 | Pages | 1905-14 |
| PubMed ID | 22238458 | Mgi Jnum | J:181195 |
| Mgi Id | MGI:5309060 | Doi | 10.4049/jimmunol.1101978 |
| Citation | Fauconnier M, et al. (2012) IL-12Rbeta2 is essential for the development of experimental cerebral malaria. J Immunol 188(4):1905-14 |
| abstractText | A Th1 response is required for the development of Plasmodium berghei ANKA (PbA)-induced experimental cerebral malaria (ECM). The role of pro-Th1 IL-12 in malaria is complex and controversial. In this study, we addressed the role of IL-12Rbeta2 in ECM development. C57BL/6 mice deficient for IL-12Rbeta2, IL-12p40, or IL-12p35 were analyzed for ECM development after blood-stage PbA infection in terms of ischemia and blood flow by noninvasive magnetic resonance imaging and angiography, T cell recruitment, and gene expression. Without IL-12Rbeta2, no neurologic sign of ECM developed upon PbA infection. Although wild-type mice developed distinct brain microvascular pathology, ECM-resistant, IL-12Rbeta2-deficient mice showed unaltered cerebral microcirculation and the absence of ischemia after PbA infection. In contrast, mice deficient for IL-12p40 or IL-12p35 were sensitive to ECM development. The resistance of IL-12Rbeta2-deficient mice to ECM correlated with reduced recruitment of activated T cells and impaired overexpression of lymphotoxin-alpha, TNF-alpha, and IFN-gamma in the brain after PbA infection. Therefore, IL-12Rbeta2 signaling is essential for ECM development but independent from IL-12p40 and IL-12p35. We document a novel link between IL-12Rbeta2 and lymphotoxin-alpha, TNF-alpha, and IFN-gamma expression, key cytokines for ECM pathogenesis. |
